Skip to main content
main-content

The independent medical news service

Prostate cancer

28-11-2018 | Oncology | News | Article

Editor's pick

Multiparametric MRI does not render systematic prostate biopsy obsolete

Pre-biopsy multiparametric magnetic resonance imaging improves the detection of clinically significant prostate cancer in biopsy-naive patients but does not appear to remove the need for systematic biopsy, MRI-FIRST study data show.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30569-2
Lancet Oncol 2018; doi:10.1016/ S1470-2045(18)30607-7

22-11-2018 | Oncology | Main feed | News

Boosted surgical approach can match radiotherapy for prostate cancer survival

Treatment with radical prostatectomy plus adjuvant external beam radiotherapy and androgen deprivation therapy can offer equivalent survival outcomes to a nonsurgical approach in patients with high-risk prostate cancer, research shows.

Source:

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.4836

09-11-2018 | Prostate cancer | News | Article

NCRI 2018 in brief

Prostate cancer patients willing to make trade-offs between survival, side effects

Men with a new diagnosis of nonmetastatic prostate cancer say they would accept small reductions in survival odds if that meant fewer side effects and an improved quality of life, suggests the COMPARE study.

06-11-2018 | Oncology | Main feed | News

NCRI 2018

Run-in period may improve adherence to aspirin for chemoprevention

In patients undergoing radical therapy for cancer, an 8-week run-in period of aspirin is acceptable and well tolerated, and could reduce the risk for nonadherence and participant attrition in adjuvant and prevention trials, say researchers.

Source:

NCRI 2018; Glasgow, UK

02-11-2018 | Prostate cancer | News | Article

ESMO 2018

STAMPEDE suggests radiation OS benefit for select metastatic prostate cancer patients

The latest results from the STAMPEDE trial do not show an additional overall survival benefit with radiotherapy for men undergoing androgen deprivation therapy with or without docetaxel for newly diagnosed metastatic prostate cancer.

Source:

ESMO 2018; Munich, Germany; 19–23 October

Lancet 2018; doi:10.1016/ S0140-6736(18)32486-3

25-10-2018 | Oncology | News | Article

ESMO 2018 in brief

LHRH therapy may be SPAREd for abiraterone-treated mCRPC patients

Men with metastatic castration-resistant prostate cancer who are beginning treatment with abiraterone acetate plus prednisone may not need luteinizing hormone-releasing hormone therapy, suggest exploratory findings presented at the ESMO 2018 Congress in Munich, Germany.

18-10-2018 | Oncology | Main feed | News

Long-term PFS benefits of pelvic irradiation shown in prostate cancer

An updated analysis of the NRG/RTOG 9413 trial shows that the benefits of whole pelvic radiotherapy plus neoadjuvant hormonal therapy persist in the long term in patients with intermediate- or high-risk localised prostate cancer.

Source:

Lancet Oncol 2018; doi:10.1016/ S1470-2045(18)30528-X
Lancet Oncol 2018; doi:10.1016/ S1470-2045(18)30588-6

14-09-2018 | Prostate cancer | News | Article

Editor's pick

Meta-analysis consolidates evidence against PSA-based screening

Prostate-specific antigen-based screening may lead to a modest reduction in prostate cancer-specific mortality but has no effect on overall survival, say the authors of a meta-analysis published in The BMJ.

Source:

BMJ 2018; 362: k3519, k3702

13-09-2018 | Prostate cancer | News | Article

HRQoL unaffected by addition of apalutamide to androgen deprivation therapy

The addition of apalutamide to androgen deprivation therapy has no detrimental effect on health-related quality of life in men with nonmetastatic castration-resistant prostate cancer, an analysis of data from the SPARTAN trial shows.

Source:

Lancet Oncology 2018; doi:10.1016/S1470-2045(18)30456-X

04-09-2018 | Prostate cancer | News | Article

Steroid SWITCHing may benefit mCRPC patients who progress on abiraterone

A phase II proof-of-concept study has shown that clinically stable patients with metastatic castration-resistant prostate cancer and limited disease progression during treatment with abiraterone acetate plus prednisone can experience biochemical and radiologic responses following a steroid switch to dexamethasone.

Source:

Br J Cancer 2018; doi:10.1038/s41416-018-0123-9

31-08-2018 | Prostate cancer | News | Article

Moderately hypofractionated radiotherapy regimen promising for localized prostate cancer

Intensity-modulated radiation therapy using a moderately hypofractionated, dose-escalated regimen may control localized prostate cancer better than a conventional regimen while shortening treatment duration, a phase III trial suggests.

Source:

J Clin Oncol 2018; doi:10.1200/JCO.2018.77.9868

23-08-2018 | Oncology | News | Article

New molecular target classification system could aid treatment decision making

The ESMO Translational Research and Precision Medicine Working Group has proposed a classification system that orders the value of molecular aberrations as oncologic clinical targets based on the supporting evidence available.

Source:

Ann Oncol 2018; doi:10.1093/annonc/mdy263

27-07-2018 | Prostate cancer | News | Article

Editor's pick

Robot-assisted laparoscopy meets open radical prostatectomy for functional outcomes

Phase III trial findings suggest that men who require radical prostatectomy for localised prostate cancer achieve similar functional outcomes at 2 years, regardless of whether they undergo robot-assisted laparoscopic surgery or an open radical retropubic procedure.

Source:

Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30357-7
Lancet Oncol 2018; doi:10.1016/S1470-2045(18)30417-0

19-07-2018 | Prostate cancer | Main feed | News

approvalsWatch

Enzalutamide receives FDA approval for nonmetastatic CRPC

Find out more here

13-07-2018 | Prostate cancer | News | Article

Editor's pick

Pembrolizumab tested in previously treated mCRPC

The PD-1 inhibitor pembrolizumab shows antitumor activity in patients with previously treated metastatic castration-resistant prostate cancer, indicate results from the KEYNOTE-028 and KEYNOTE-199 trials.

Source:

Ann Oncol 2018; doi:10.1093/annonc/mdy232, ASCO Annual Meeting 2018; Chicago, Illinois, USA

11-07-2018 | Prostate cancer | News | Article

PSMA-targeted nanoparticle agent is active against mCRPC

Research published in JAMA Oncology points to the efficacy of a prostate-specific membrane antigen-directed docetaxel-containing nanoparticle in patients with metastatic castration-resistant prostate cancer.

Source:

JAMA Oncol 2018; doi:10.1001/jamaoncol.2018.2168

06-07-2018 | Prostate cancer | News | Article

AR-V7 status could inform treatment choice in mCRPC

Researchers have used a protein-based assay to confirm the validity of nuclear-localized androgen receptor splice variant 7 protein as a predictor of response to therapy for metastatic castration-resistant prostate cancer.

Source:

JAMA Oncol 2018; Advance online publication

05-06-2018 | Prostate cancer | News | Article

ASCO 2018

Metastatic CRPC outcomes no worse for Black versus White men

Two studies reported at the ASCO Annual Meeting 2018 show that Black men with metastatic castration-resistant prostate cancer fare as well as White men, if not better, when treated with abiraterone or chemotherapy in the clinical trial setting.

Source:

ASCO Annual Meeting 2018; Chicago, Illinois, USA

05-06-2018 | Prostate cancer | News | Article

ASCO 2018

Olaparib has clinical efficacy in men with metastatic castration-resistant prostate cancer

 Addition of olaparib to abiraterone is associated with increased radiographic progression-free survival in unselected patients with metastatic castration-resistant prostate cancer, show study findings.

Source:

Lancet Oncol 2018; Advance online publication

25-05-2018 | Prostate cancer | News | Article

Editor's pick

Further data support aBSI as a prognostic marker in mCRPC

Prospective data confirm use of the automated Bone Scan Index as an independent prognostic marker of survival and other clinical outcomes in men with metastatic castration-resistant prostate cancer, researchers report.

Source:

JAMA Oncol 2018; Advance online publication

image credits